Tag: KDC-MN-091

  • PT-141 (Bremelanotide)

    Melanocortin-4 receptor agonist

    A FDA-approved (2019) melanocortin receptor agonist (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, derived from melanotan II.

    Abstract

    Bremelanotide (Vyleesi; PT-141; CAS 189691-06-3; molecular formula C50H68N14O10; molecular weight 1025.18) is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The compound is derived from the alpha-MSH analog melanotan II by structural modification that increased selectivity toward MC4 versus MC1 (reducing the skin pigmentation activity prominent in melanotan II). PT-141 was originally developed as a sunless tanning agent before pivoting to sexual function applications when central effects were observed. Mechanism is melanocortin-4 receptor agonism in the central nervous system, with downstream effects on dopaminergic and oxytocinergic pathways implicated in sexual response. The compound is administered subcutaneously prior to anticipated sexual activity. Pharmacokinetics: plasma half-life approximately 2.7 hours; the central effect persists 4 to 6 hours after administration. Adverse events include nausea (highest frequency), hyperpigmentation with chronic use, and modest blood pressure elevation.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.